Interspecies comparison of the antiplatelet, antithrombotic, and hemorrhagic effects of SR 121566A, a novel nonpeptide GP IIb/IIIa antagonist

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 6, 1999, Pages 897-904

  Bernat, A ^a   Hoffmann, P ^a   Savi, P ^a   Lale A ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

Aggregation; GP IIb IIIa; Platelets; SR121566A; Thrombosis

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; 3 [N [4 [4 (AMINOIMINOMETHYL)PHENYL] 1,3 THIAZOL 2 YL] N (CARBOXYMETHYL) PIPERIDIN 4 YL]AMINOPROPIONIC ACID; 4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; 4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID HYDROCHLORIDE TRIHYDRATE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; N [N [5 [4 (AMINOIMINOMETHYL)PHENYL]PENTANOYL]ASPARTYL]PHENYLALANINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; BENZYLAMINES; DOGS; FIBRINOLYTIC AGENTS; GUINEA PIGS; HEMORRHAGE; HUMANS; MALE; MICE; PAPIO; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RABBITS; RATS; SPECIES SPECIFICITY; THIAZOLES;

EID: 0033014331     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199906000-00010     Document Type: Article

References (24)

1. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989;80:749.
2. Topol EJ. Targeted approaches to thrombus inhibition: an end to the shotgun approach. Clin Cardiol 1997;20:I-22.
3. Harfenist EJ, Packham MA, Mustard JF. Effects of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits and rats. Blood 1988;71:132.
4. Verhallen PFJ, Barth M. Species comparison of anti-aggregatory properties of three fibrinogen receptor antagonists: RGDS, echistatin and the carboxyterminal dodecapeptide of the fibrinogen gamma chain. Thromb Haemost 1991;65:1144.
5. Nicholson NS, Panzer-Knodle SG, Salyers AK, et al. In vitro and in vivo effects of a peptide mimetic (SC-47643) on RGD as an antiplatelet and antithrombotic agent. Thromb Res 1991;62:567.
6. Kaku S, Umemura K, Mizuno A, Kawasaki T, Nakashima M. Evaluation of the disintegrin, triflavin, in a rat middle cerebral artery thrombosis model. Eur J Pharmacol 1997;321:301.
7. Bostwick JS, Kasiewski CJ, Chu V, et al. Antithrombotic activity of RG13965: a novel platelet fibrinogen receptor antagonist. Tromb Res 1996;82:495.
8. Savi P, Badorc A, Lale A, et al. SR 121787: a new orally active fibrinogen receptor antagonist. Thromb Haemost 1998;80:469-76.
9. Hoffmann P, Bernat A, Savi P, Herbert JM. Antiplatelet and antithrombotic efficacy of SR 121787: a non-peptide orally active GPIIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin. J Cardiovasc Pharmacol 1997;30:360.
10. Cox D. Integrins and cardiovascular disease. Exp Opin Invest Drugs 1995;4:413.
11. Nicholson NS, Panzer-Knodle SG, King LW, et al. SC-49992 - A potent and specific inhibitor of platelet aggregation. Thromb Res 1994;74:523.
12. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927.
13. Herbert JM, Bernat A, Barthelemy G, Dol F, Rinaldi M. Antithrombotic activity of SR 46349: a novel, potent and selective 5-HT2 receptor antagonist. Thromb Haemost 1993;69:262.
14. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701: comparison with the synthetic pentasaccharide (SR 90107/ORG 31540) and standard heparin. Circ Res 1996;79:590.
15. Cox D, Motoyama Y, Seki J, Aoki T, Dohi M, Yoshida K. Pentamadine: a non-peptide GPIIb/IIIa antagonist - in vitro studies on platelets from humans and other species. Thromb Haemost 1992; 68:731.
16. Cook NS, Zerwes H-G, Tapparelli C, et al. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists. Thromb Haemost 1993;70:531.
17. Jennings LK, White MM, Mandrell TD. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb-IIIa functional activity. Thromb Haemost 1995;74:1551.
18. 1 and argatropan. J Pharmacol Exp Ther 1996;277:502.
19. Vogel GMT, Meuleman DG, Bourgondiën FGM, Hobbelen PMJ. Comparison of two experimental thrombosis models in rats: effects of four glycosaminoglycans. Thromb Res 1989;54:399.
20. Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Müller TH. Antagonism of the GPIIb/IIIa receptor with the non-peptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo. J Cardiovasc Pharmacol 1997;30:261.
21. Kaku S, Kawasaki T, Hisamichi N, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost 1996;75:679.
22. Krupski WC, Bass A, Kelly AB, Ruggeri ZM, Harker LA, Hanson SR. Interruption of vascular thrombosis by bolus antiplatelet glycoprotein IIb/IIIa monoclonal antibodies in baboons. J Vasc Surg 1993;17:294.
23. 3 receptor blockage with peptide TP9301 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time. J Lab Clin Med 1994;124:589.
24. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547.